Alprostadil vs Oxytocin
A side-by-side research comparison of Alprostadil and Oxytocin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Alprostadil | Oxytocin |
|---|---|---|
| Full name | Alprostadil (Prostaglandin E1) | Oxytocin (OXT) |
| Category | Sexual Health | Sexual Health |
| Status | FDA-approved drug (prescription) | FDA Approved |
| Mechanism | Alprostadil activates prostaglandin receptors that raise intracellular cAMP in cavernosal smooth muscle, causing vasodilation and increased blood inflow to produce an erection regardless of nerve signaling or arousal. | Binds OXTR in social cognition brain regions (amygdala, nucleus accumbens) and reproductive organs. Modulates serotonin and dopamine in reward circuits. |
| Molecular weight | 354.5 Da | 1,007 Da |
| Half-life | Very short (minutes, locally metabolized) | 3-5 min (IV) / 20-30 min (intranasal) |
| Bioavailability | Intracavernosal injection or intraurethral suppository | Low (oral), Moderate (intranasal ~2-5%) |
| Typical dose | Provider-titrated per response | 20-40 IU intranasal |
| Frequency | As needed before activity | As needed or daily |
| Route | Intracavernosal injection or urethral pellet | Intranasal or IV (obstetric) |
Alprostadil reported benefits
- Effective for erectile dysfunction
- Works independent of arousal
- Rapid onset
- Useful when oral PDE5 inhibitors fail
Oxytocin reported benefits
- Enhanced social bonding
- Improved intimacy
- Anxiolytic effects
- Pain modulation
- Post-orgasmic well-being
Related comparisons
Research and educational reference only. Not medical advice.